News AHA: AZ's baxdrostat impresses in resistant hypertension AstraZeneca's data reveal for resistant hypertension treatment baxdrostat suggests its optimism about big sales for the drug could be justified.
News AHA: Cash for drug adherence study has disappointing result People with hypertension were twice as likely to take medicine regularly when offered cash rewards, but that didn't improve their blood pressure.
News George's triple therapy for hypertension hits mark in stroke George Medicines' new triple pill for hypertension delivers a much-needed win in a phase 3 trial in haemorrhagic stroke.
News AZ chalks up another positive trial for hypertension drug AstraZeneca's baxdrostat has hit the mark in another phase 3 trial in resistant hypertension, keeping it on track for filing later this year.
News Apple Watch hypertension feature cleared by FDA The latest Apple Watch will include a just-approved health feature that will warn users if they show signs of chronic hypertension.
News ESC: 'Landmark' study backs AZ's baxdrostat for hypertension The race to market is on with Mineralys, as AstraZeneca showcases data for aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension.
News Sandoz launches first biosimilar Tysabri in US Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.